EANS-News: SYGNIS Pharma AG / SYGNIS strengthens patent position on AX200 for the treatment of neurodegenerative diseases

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Licensing Agreements

Heidelberg (euro adhoc) - SYGNIS strengthens patent position on AX200
for the treatment of neurodegenerative diseases

Heidelberg, 09 February 2011 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard), a clinical stage
biotech company developing innovative therapies for the treatment
of neurodegenerative diseases, today announced that it has
licensed the exclusive rights to a European patent, which will
significantly expand SYGNIS´ IP-position with regard to its lead
candidate AX200. AX200, which is known as the G-CSF protein, is
currently in a clinical phase II efficacy trial for the treatment
of acute ischemic stroke (AXIS 2).

The licence covers an issued patent which provides broad protection
with regard to the use of G-CSF for the reorganisation of
neural tissue affected by neurodegenerative diseases, especially
stroke or trauma. The patent rights strengthen SYGNIS´
IP-position around AX200 in the current AXIS 2-trial and also
cover the use of G-CSF for the treatment of patients in the
early rehabilitation-phase following a stroke. The patent has a
scheduled expiry date of 2022, not including any potential
extensions. In this respect, it complements the patent, granted
in Europe in 2006 and in the USA in 2009, covering the use
of AX200 for the treatment of stroke by stimulating
arteriogenesis, to which SYGNIS has exclusive access under a license
agreement with the Max-Planck Gesellschaft.

Dr Frank Rathgeb, Chief Medical Officer of SYGNIS, said: "These
exclusive patent rights further strengthen the significant
therapeutic potential of AX200. The current phase II efficacy trial
for the treatment of acute ischemic stroke is progressing well and
we expect to report the top-line data in the second half of
2011. Our robust intellectual property position means we are in a
strong position to maximise the market potential of AX200."

About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,
is a specialty pharmaceutical company listed on the Prime Standard
of the German stock exchange. The Company is focused on the
research and development of innovative therapies for the
treatment of disorders of the Central Nervous System. SYGNIS´ core
projects are currently Acute Stroke for which SYGNIS´ lead clinical
programme is AX200 as well as the preclinical KIBRA-project for
the treatment of different forms of dementia. All these disorders
are characterized by the fact that, as the disease progresses,
nerve cells are damaged and die. Although there is great medical
demand, there are currently no or only inadequate treatment
options available. SYGNIS´ strategy for growth includes the
development of new products from its own research and through
in-licensing and acquisitions.

For further information please contact:
SYGNIS Pharma AG:
Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward- looking, i.e. not definite.
Such statements are mainly predictions of future results, trends,
plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by
other factors as a consequence of which the actual results, plans
and goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise
these statements in the light of new information or future results
or for any other reason. ###

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE000A1E9B74
WKN: A1E9B7
Index: CDAX, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade